Capsule Summary Slidesets

Share

Program Content

Activities

  • VenDd in t(11;14) RR MM
    Phase I/II Trial of Venetoclax/Dara/Dex (VenDd) vs Bortezomib/Dara/Dex (DVd) in t(11;14) R/R MM: Updated Analysis of MRD Negativity
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

  • CENTAURUS Final Analysis
    CENTAURUS: Final Analysis of Phase II Study With Daratumumab Monotherapy in Intermediate- or High-Risk Smoldering MM
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2023

  • IsKia EMN24 in ND MM
    IsKia EMN24: Phase III Trial of IsaKRd vs KRd in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2023

  • LINKER-MM1 Update
    LINKER-MM1 Update: Phase I/II Trial of Anti-BCMAxCD3 Bispecific Antibody Linvoseltamab in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • DRVd vs RVd Real World
    D-RVd vs RVd for Newly Diagnosed Transplant-Eligible Patients With Multiple Myeloma: Real-world Outcomes
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • PERSEUS Primary Analysis
    PERSEUS: Primary Analysis of Phase III Trial With VRd ± Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Eligible for ASCT
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

  • MonumenTAL-1 Modified Dosing
    MonumenTAL-1: Impact of Dose Modification on Safety and Efficacy of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.